Literature DB >> 19067146

The degradation of glycosaminoglycans by intestinal microflora deteriorates colitis in mice.

Hye-Sung Lee1, Song-Yi Han, Kwon-Yeul Ryu, Dong-Hyun Kim.   

Abstract

The biosynthesis and modification of mucopolysaccharides and glycosaminoglycans (GAGs), secreted from gastrointestinal mucosal cells, are increased in colitis and influence the viability of the defense barrier. Therefore, to evaluate the role of GAG-degrading intestinal microflora during the progression of colitis, we investigated the degradation activity of intestinal bacterial GAG, cytotoxicity of GAGs and their metabolites, such as iduronic acid, D: -uronic acid or D: -glucuronic acid and D: -galactosamine or D: -glucosamine, against intestinal cells. We also tested their deteriorative effects against colitis. Colitis was induced using 2,4,6-trinitrobenzene sulfonic acid (TNBS) with and without antibiotics in mice. The TNBS treatment caused colon shortening, increased myeloperoxidase activity, induced IL-1beta, TNF-alpha, and IL-6 expression in the colon, activated NF-kappaB, and potentiated the GAG-degrading activities of intestinal microflora. The antibiotic treatment inhibited colon shortening, decreased myeloperoxidase activity, and reduced proinflammatory cytokine expression, NF-kappaB activation, and GAG degradation, induced by TNBS. Among the GAG metabolites, d-glucosamine and d-galactosamine showed cytotoxicity against intestinal cells, Caco-2 and IEC-18 cells, synergistically deteriorated the cytotoxicity of TNBS as well as the TNBS-induced colitis in mice. Based on these findings, intestinal microflora may degrade GAGs in colitis, their metabolites deteriorate the progress of colitis and antibiotics ameliorate the colitis by the inhibition of GAG-degrading bacterial growth.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19067146     DOI: 10.1007/s10753-008-9099-6

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  32 in total

Review 1.  Induction of cyclo-oxygenase and nitric oxide synthase in inflammation.

Authors:  I Appleton; A Tomlinson; D A Willoughby
Journal:  Adv Pharmacol       Date:  1996

2.  Faecal mucus degrading glycosidases in ulcerative colitis and Crohn's disease.

Authors:  J M Rhodes; R Gallimore; E Elias; R N Allan; J F Kennedy
Journal:  Gut       Date:  1985-08       Impact factor: 23.059

3.  Studies of intestinal microflora. V. Fecal microbial ecology in ulcerative colitis and regional enteritis: relationship to severity of disease and chemotherapy.

Authors:  S L Gorbach; L Nahas; A G Plaut; L Weinstein; J F Patterson; R Levitan
Journal:  Gastroenterology       Date:  1968-04       Impact factor: 22.682

Review 4.  Cytokines in intestinal inflammation: pathophysiological and clinical considerations.

Authors:  R B Sartor
Journal:  Gastroenterology       Date:  1994-02       Impact factor: 22.682

5.  Acid hydrolases in monocytes from patients with inflammatory bowel disease, chronic liver disease, and rheumatoid arthritis.

Authors:  N K Ganguly; J G Kingham; B Lloyd; R S Lloyd; C P Price; D R Triger; R Wright
Journal:  Lancet       Date:  1978-05-20       Impact factor: 79.321

6.  Biochemical and immunohistochemical analysis of glycosaminoglycans in inflamed and non-inflamed intestinal mucosa of patients with Crohn's disease.

Authors:  Celso L R Belmiro; Heitor S P Souza; Celeste C S Elia; Morgana T L Castelo-Branco; Flavia R Silva; Rosane L Machado; Mauro S G Pavão
Journal:  Int J Colorectal Dis       Date:  2005-01-20       Impact factor: 2.571

Review 7.  Inflammatory bowel disease: dysfunction of GALT and gut bacterial flora (II).

Authors:  P Chandran; S Satthaporn; A Robins; O Eremin
Journal:  Surgeon       Date:  2003-06       Impact factor: 2.392

8.  Myeloperoxidase activity as a quantitative assessment of neutrophil infiltration into ischemic myocardium.

Authors:  K M Mullane; R Kraemer; B Smith
Journal:  J Pharmacol Methods       Date:  1985-11

9.  Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease.

Authors:  I I Singer; D W Kawka; S Schloemann; T Tessner; T Riehl; W F Stenson
Journal:  Gastroenterology       Date:  1998-08       Impact factor: 22.682

10.  Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice.

Authors:  H C Rath; M Schultz; R Freitag; L A Dieleman; F Li; H J Linde; J Schölmerich; R B Sartor
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

View more
  13 in total

1.  Gut Microbiome Function Predicts Response to Anti-integrin Biologic Therapy in Inflammatory Bowel Diseases.

Authors:  Ashwin N Ananthakrishnan; Chengwei Luo; Vijay Yajnik; Hamed Khalili; John J Garber; Betsy W Stevens; Thomas Cleland; Ramnik J Xavier
Journal:  Cell Host Microbe       Date:  2017-05-10       Impact factor: 21.023

Review 2.  Role of the Microbiome in the Pathogenesis of COVID-19.

Authors:  Rituparna De; Shanta Dutta
Journal:  Front Cell Infect Microbiol       Date:  2022-03-31       Impact factor: 5.293

3.  CSA13 inhibits colitis-associated intestinal fibrosis via a formyl peptide receptor like-1 mediated HMG-CoA reductase pathway.

Authors:  Chunlan Xu; Sally Ghali; Jiani Wang; David Q Shih; Christina Ortiz; Caroline C Mussatto; Elaine C Lee; Diana H Tran; Jonathan P Jacobs; Venu Lagishetty; Phillip Fleshner; Lori Robbins; Michelle Vu; Tressia C Hing; Dermot P B McGovern; Hon Wai Koon
Journal:  Sci Rep       Date:  2017-11-27       Impact factor: 4.379

4.  The reduction of DSS-induced colitis severity in mice exposed to cigarette smoke is linked to immune modulation and microbial shifts.

Authors:  Giuseppe Lo Sasso; Blaine W Phillips; Alain Sewer; James N D Battey; Athanasios Kondylis; Marja Talikka; Bjoern Titz; Emmanuel Guedj; Dariusz Peric; David Bornand; Remi Dulize; Celine Merg; Maica Corciulo; Sonia Ouadi; Rendy Yanuar; Ching Keong Tung; Nikolai V Ivanov; Manuel C Peitsch; Julia Hoeng
Journal:  Sci Rep       Date:  2020-03-02       Impact factor: 4.379

5.  Dietary Fiber Pectin Ameliorates Experimental Colitis in a Neutral Sugar Side Chain-Dependent Manner.

Authors:  Keita Ishisono; Toshiyuki Mano; Tomio Yabe; Kohji Kitaguchi
Journal:  Front Immunol       Date:  2019-12-19       Impact factor: 7.561

Review 6.  The gut microbiota in osteoarthritis: where do we stand and what can we do?

Authors:  Xiaoxia Hao; Xingru Shang; Jiawei Liu; Ruimin Chi; Jiaming Zhang; Tao Xu
Journal:  Arthritis Res Ther       Date:  2021-01-27       Impact factor: 5.156

7.  Disparities in the gut metabolome of post-operative Hirschsprung's disease patients.

Authors:  Vera Plekhova; Ellen De Paepe; Katrien Van Renterghem; Myriam Van Winckel; Lieselot Y Hemeryck; Lynn Vanhaecke
Journal:  Sci Rep       Date:  2021-08-09       Impact factor: 4.379

8.  Highly Heterogeneous Probiotic Lactobacillus Species in Healthy Iranians with Low Functional Activities.

Authors:  Mahdi Rohani; Nasrin Noohi; Malihe Talebi; Mohammad Katouli; Mohammad R Pourshafie
Journal:  PLoS One       Date:  2015-12-08       Impact factor: 3.240

9.  The Effects of Glucosamine and Chondroitin Sulfate on Gut Microbial Composition: A Systematic Review of Evidence from Animal and Human Studies.

Authors:  Anna Shmagel; Ryan Demmer; Daniel Knights; Mary Butler; Lisa Langsetmo; Nancy E Lane; Kristine Ensrud
Journal:  Nutrients       Date:  2019-01-30       Impact factor: 5.717

10.  Intestinal inflammation alters mucosal carbohydrate foraging and monosaccharide incorporation into microbial glycans.

Authors:  Gisela Adrienne Weiss; Thomas Grabinger; Jesus Glaus Garzon; Tobias Hasler; Anna Greppi; Christophe Lacroix; Nikolay Khanzhin; Thierry Hennet
Journal:  Cell Microbiol       Date:  2020-10-06       Impact factor: 3.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.